{"id":232061,"date":"2026-02-25T09:07:06","date_gmt":"2026-02-25T15:07:06","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/molecular-glue-from-this-san-diego-startup-makes-cancer-self-destruct-clinical-trial-begins"},"modified":"2026-02-25T09:07:06","modified_gmt":"2026-02-25T15:07:06","slug":"molecular-glue-from-this-san-diego-startup-makes-cancer-self-destruct-clinical-trial-begins","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/molecular-glue-from-this-san-diego-startup-makes-cancer-self-destruct-clinical-trial-begins","title":{"rendered":"\u2018Molecular glue\u2019 from this San Diego startup makes cancer self-destruct: Clinical trial begins"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/molecular-glue-from-this-san-diego-startup-makes-cancer-self-destruct-clinical-trial-begins2.jpg\"><\/a><\/p>\n<p>This local biotech says it has found a way to trick cancer cells into destroying themselves with its molecular glue. Now it\u2019s putting that claim to the test. After attracting global attention from researchers and billions of dollars from Big Pharma, Neomorph announced that it has begun its first clinical trial. The molecular glue aims to treat a form of kidney cancer.<\/p>\n<p>The first trial will dose one patient with the molecular glue, NEO-811, to treat clear cell renal cell carcinoma, the most common kind of kidney cancer.<\/p>\n<p>In San Diego County, roughly 500 people are diagnosed with kidney cancer each year\u2014that\u2019s more than one new case every day, according to the California Cancer Registry. Among residents 65 and older, the rate jumps to more than four times higher than the overall population: 2,000 San Diegan\u2019s over 65 are diagnosed with a form of kidney cancer each year.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This local biotech says it has found a way to trick cancer cells into destroying themselves with its molecular glue. Now it\u2019s putting that claim to the test. After attracting global attention from researchers and billions of dollars from Big Pharma, Neomorph announced that it has begun its first clinical trial. The molecular glue aims [\u2026]<\/p>\n","protected":false},"author":707,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-232061","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/707"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=232061"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/232061\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=232061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=232061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=232061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}